Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,208.12
+80.43 (+7.13%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
99
100
Next >
Eli Lilly & Co (NYSE:LLY) Stands Out in Recent CANSLIM Growth Stock Screen
↗
February 05, 2026
Via
Chartmill
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
↗
February 05, 2026
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Via
The Motley Fool
LLY Q4 Deep Dive: Obesity Medicines, Pipeline Progress, and Market Expansion Drive Outperformance
February 05, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year...
Via
StockStory
Why Eli Lilly Stock Soared Today
↗
February 04, 2026
The healthcare giant gained nearly $100 billion in market value.
Via
The Motley Fool
Eli Lilly Stock Notches Best Day In 9 Months: Touts $50 Medicare For Obesity Drugs As ‘Compelling Value Proposition’ After Q4 Beat
↗
February 04, 2026
Via
Stocktwits
Eli Lilly & Co. (NYSE:LLY) Soars on Blockbuster Q4 Earnings and Upbeat 2026 Guidance
↗
February 04, 2026
Via
Chartmill
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report
↗
February 03, 2026
Via
Stocktwits
Explore the top gainers and losers within the S&P500 index in today's session.
↗
February 04, 2026
Via
Chartmill
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
↗
February 04, 2026
Novo Nordisk shares slide after weak 2026 guidance, while Eli Lilly rallies on strong earnings, booming weight loss drug sales, and a broader pipeline advantage.
Via
Benzinga
Wednesday's session: top gainers and losers in the S&P500 index
↗
February 04, 2026
Via
Chartmill
Nasdaq Dips Over 400 Points; Eli Lilly Shares Surge Following Upbeat Earnings
↗
February 04, 2026
Via
Benzinga
Eli Lilly Q4 2025 Earnings Call Transcript
↗
February 04, 2026
Eli Lilly and Company (NYSE:LLY) reported fourth-quarter financial results on Wednesday. The transcript from the earnings call has been provided below.
Via
Benzinga
Topics
Earnings
Eli Lilly (LLY) Stock Trades Up, Here Is Why
February 04, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 10% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street expectations and issued an...
Via
StockStory
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
↗
February 04, 2026
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.
Via
The Motley Fool
Eli Lilly (LLY) Q4 2025 Earnings Call Transcript
↗
February 04, 2026
Eli Lilly (LLY) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance
↗
February 04, 2026
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...
Via
Stocktwits
Topics
Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
February 04, 2026
Via
Chartmill
Q4 Earnings Summary: Eli Lilly And AbbVie Beat, Uber Mixed
↗
February 04, 2026
Quarterly earnings reveal a mix of positive surprises and challenges, with Eli Lilly and AbbVie beating expectations and Uber facing hurdles.
Via
Talk Markets
Eli Lilly Surges 9% After Obliterating Forecasts As Mounjaro, Zepbound Sales Double
↗
February 04, 2026
The drugmaker smashed Q4 expectations and guided up on its obesity treatments.
Via
Investor's Business Daily
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook
↗
February 04, 2026
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.
Via
Stocktwits
Eli Lilly (NYSE:LLY) Reports Strong Q4 CY2025, Stock Soars
February 04, 2026
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year...
Via
StockStory
Does Stanley Druckenmiller Know Something Wall Street Doesn't? He Dumped All of His Shares in a Company Dominating a Market That May Soon Be Worth $100 Billion and Opened Positions in 3 AI Giants.
↗
February 04, 2026
Druckenmiller has renewed his AI bet.
Via
The Motley Fool
Topics
Artificial Intelligence
Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season?
↗
February 03, 2026
Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.
Via
Stocktwits
Topics
Intellectual Property
Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
↗
February 03, 2026
While riding high on the popularity of its weight loss drug Zepbound, the company is quietly building a presence in a cutting-edge healthcare segment.
Via
The Motley Fool
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
↗
February 03, 2026
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
Stocks
The Smartest Growth Stock to Buy With $30 Right Now
↗
February 03, 2026
This pre-revenue biopharmaceutical stock is a home run swing worth taking.
Via
The Motley Fool
As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?
February 03, 2026
Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.
Via
Barchart.com
Veteran Biopharma Engineer Ge Yang Attracts Investor Interest with Vision to Redefine Global Pharma Manufacturing
February 03, 2026
Via
AB Newswire
If You Invested $100 In Eli Lilly and Co Stock 5 Years Ago, You Would Have This Much Today
↗
February 03, 2026
Via
Benzinga
Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?
February 03, 2026
Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.
Via
Barchart.com
Topics
ETFs
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.